Pub Date : 2023-07-25DOI: 10.1097/jd9.0000000000000328
{"title":"Successful Treatment of Severe Pityriasis Rubra Pilaris with Cyclosporine A in An Infant: Erratum","authors":"","doi":"10.1097/jd9.0000000000000328","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000328","url":null,"abstract":"","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46197828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.1097/jd9.0000000000000331
{"title":"Liponeurofibroma: Erratum","authors":"","doi":"10.1097/jd9.0000000000000331","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000331","url":null,"abstract":"","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44292156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.1097/jd9.0000000000000327
{"title":"Toe absence related to verrucous carcinoma: Erratum","authors":"","doi":"10.1097/jd9.0000000000000327","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000327","url":null,"abstract":"","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48151185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-03DOI: 10.1097/jd9.0000000000000326
Thi Thu Hien Do, Thai Minh Hao Nguyen, T. Kanekura
Combination therapy of a 308 nm monochromatic excimer lamp and topical tacrolimus is widely used in the treatment of localized vitiligo; however, there are no published studies investigating this combination therapy in Vietnamese patients with vitiligo. This study was performed to evaluate the efficacy of combined excimer lamp and topical tacrolimus therapy for patients with localised vitiligo in Vietnam. We performed a pre-post clinical trial of 30 patients diagnosed with localised vitiligo in Vietnam. The patients were treated with an excimer lamp twice weekly and with topical tacrolimus twice daily. Effectiveness was evaluated based on the reduction rate of the vitiligo area scoring index (VASI). After 12 weeks of treatment, response was excellent or good in 16 patients (53.3%), moderate in 8 patients (26.7%), and poor in 6 patients (20%). The excellent or good responses increased over time from 3 patients (10%) at 6 weeks to 16 patients (53.3%) at 12 weeks (p=0.001). Earlier initiation of repigmentation was associated with a better response to treatment (r=-0.71; p=0.02). Patients with a perifollicular repigmentation pattern responded better to treatment than those with combined or marginal repigmentation patterns (p=0.003). Side effects occurred in 13 patients (43.3%), including burning (43.3%), pruritus (10%), and mild blistering (6.7%), and none of these interrupted the treatment. Combination therapy with excimer lamp and topical tacrolimus appears to be effective and safe in treating patients with localised vitiligo in Vietnam.
{"title":"EFFICACY OF 308 NM MONOCHROMATIC EXCIMER LAMP AND TOPICAL TACROLIMUS COMBINATION THERAPY IN LOCALIZED VITILIGO: A STUDY IN VIETNAM","authors":"Thi Thu Hien Do, Thai Minh Hao Nguyen, T. Kanekura","doi":"10.1097/jd9.0000000000000326","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000326","url":null,"abstract":"\u0000 \u0000 Combination therapy of a 308 nm monochromatic excimer lamp and topical tacrolimus is widely used in the treatment of localized vitiligo; however, there are no published studies investigating this combination therapy in Vietnamese patients with vitiligo. This study was performed to evaluate the efficacy of combined excimer lamp and topical tacrolimus therapy for patients with localised vitiligo in Vietnam.\u0000 \u0000 \u0000 \u0000 We performed a pre-post clinical trial of 30 patients diagnosed with localised vitiligo in Vietnam. The patients were treated with an excimer lamp twice weekly and with topical tacrolimus twice daily. Effectiveness was evaluated based on the reduction rate of the vitiligo area scoring index (VASI).\u0000 \u0000 \u0000 \u0000 After 12 weeks of treatment, response was excellent or good in 16 patients (53.3%), moderate in 8 patients (26.7%), and poor in 6 patients (20%). The excellent or good responses increased over time from 3 patients (10%) at 6 weeks to 16 patients (53.3%) at 12 weeks (p=0.001). Earlier initiation of repigmentation was associated with a better response to treatment (r=-0.71; p=0.02). Patients with a perifollicular repigmentation pattern responded better to treatment than those with combined or marginal repigmentation patterns (p=0.003). Side effects occurred in 13 patients (43.3%), including burning (43.3%), pruritus (10%), and mild blistering (6.7%), and none of these interrupted the treatment.\u0000 \u0000 \u0000 \u0000 Combination therapy with excimer lamp and topical tacrolimus appears to be effective and safe in treating patients with localised vitiligo in Vietnam.\u0000","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48364199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.1097/jd9.0000000000000325
Li-Qing Shi, Shihang Zhou, Pinglang Ruan, Bo Zhang, Yue Xin, Cheng Zhao, X. Yao, Jing-Ru Tian, Qian-Jin Lu
Heterogeneity of participants in clinical trials distorts intervention efficacy. However, factors associated with participant heterogeneity in randomized clinical trials (RCTs) focusing on systemic sclerosis (SSc) are not clear. We conducted this systematic review to establish normative standards for future research and help develop management guidelines. Three databases and four registries were searched to identify characteristics of SSc RCTs across different countries. Risk of bias was assessed by the Cochrane Collaboration’s tool and logistic regression was performed to calculate crude and adjusted ORs. In total, 261 trials met our inclusion criteria. The quality of SSc RCTs worldwide was relatively poor, with no trend of improvement in recent years, and only 12.2% were ranked as having a low risk of bias. Trials with a low risk of bias as well as single-center, single-country, or open-label trials tended to have better participant adherence than trials with a high risk of bias and multiple-center, multiple-country, or double-blind trials. Interestingly, trial registration and primary outcome definition contributed to high withdrawal. National income was also relevant; participant adherence in high-income countries, but not in upper- and lower-middle-income countries, was significantly altered by different variables. Overall, the risk of bias, national income, and trial design may lead to participant heterogeneity of SSc RCTs and ultimately confound the general clinical utility of the results. Trials with a rigorous design and transparent conduction protocol are crucial for obtaining unbiased data that can serve as a reference and for maintaining the fundamental repeatability of SSc RCTs.
{"title":"Heterogeneity of participants in interventional trials of systemic sclerosis worldwide","authors":"Li-Qing Shi, Shihang Zhou, Pinglang Ruan, Bo Zhang, Yue Xin, Cheng Zhao, X. Yao, Jing-Ru Tian, Qian-Jin Lu","doi":"10.1097/jd9.0000000000000325","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000325","url":null,"abstract":"\u0000 \u0000 Heterogeneity of participants in clinical trials distorts intervention efficacy. However, factors associated with participant heterogeneity in randomized clinical trials (RCTs) focusing on systemic sclerosis (SSc) are not clear. We conducted this systematic review to establish normative standards for future research and help develop management guidelines.\u0000 \u0000 \u0000 \u0000 Three databases and four registries were searched to identify characteristics of SSc RCTs across different countries. Risk of bias was assessed by the Cochrane Collaboration’s tool and logistic regression was performed to calculate crude and adjusted ORs.\u0000 \u0000 \u0000 \u0000 In total, 261 trials met our inclusion criteria. The quality of SSc RCTs worldwide was relatively poor, with no trend of improvement in recent years, and only 12.2% were ranked as having a low risk of bias. Trials with a low risk of bias as well as single-center, single-country, or open-label trials tended to have better participant adherence than trials with a high risk of bias and multiple-center, multiple-country, or double-blind trials. Interestingly, trial registration and primary outcome definition contributed to high withdrawal. National income was also relevant; participant adherence in high-income countries, but not in upper- and lower-middle-income countries, was significantly altered by different variables.\u0000 \u0000 \u0000 \u0000 Overall, the risk of bias, national income, and trial design may lead to participant heterogeneity of SSc RCTs and ultimately confound the general clinical utility of the results. Trials with a rigorous design and transparent conduction protocol are crucial for obtaining unbiased data that can serve as a reference and for maintaining the fundamental repeatability of SSc RCTs.\u0000","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48666854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.1097/jd9.0000000000000324
Ya-Kun Shao, Jianmin Chang
{"title":"Clear Cell Hidroacanthoma Simplex: A Case Report","authors":"Ya-Kun Shao, Jianmin Chang","doi":"10.1097/jd9.0000000000000324","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000324","url":null,"abstract":"","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47102697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-19DOI: 10.1097/jd9.0000000000000323
Fanhe Jiang, abudoureyimu Dilinuer, Lidan Mao, Jun Liang, X.‐J. Kang
{"title":"Analysis of the correlation of between CTLA4 rs231775 polymorphism and pemphigus in Xinjiang","authors":"Fanhe Jiang, abudoureyimu Dilinuer, Lidan Mao, Jun Liang, X.‐J. Kang","doi":"10.1097/jd9.0000000000000323","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000323","url":null,"abstract":"","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44258274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1097/JD9.0000000000000314
Xiaoyuan Zhong, Ying Li, Rui Ma, Xin Wang, Yingyuan Yu, N. Yu, Yangfeng Ding, Jiajing Lu, Yuling Shi
Objective: Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events (AEs) among individuals. This study aimed to determine the impact of AEs associated with acitretin treatment of moderate-to-severe plaque psoriasis on the Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS) scores. Methods: This prospective, observational, single-center study was conducted from March 2021 to June 2022 and analyzed 116 patients with moderate-to-severe plaque psoriasis treated with acitretin who were followed up for 12 weeks. The primary outcome was the incidence of AEs related to acitretin, and the secondary objective was to investigate the effect of AEs on the DLQI and HADS scores. The generalized linear models were used to assess the association between AEs related to acitretin and DLQI scores or HADS scores, and the association between the involved system/tissue and DLQI scores or HADS scores. Results: A final total of 45 patients were included in the analysis, and a total of 157 treatment-related AEs involving nine organs or systems were reported in 41 patients. The most common AE was skin- or mucosa-related, with 72 cumulative events in 31 patients. AEs also commonly affected the endocrine, digestive, and genitourinary systems. Compared with the group with 0–2 AEs, the group with 3–5 AEs had a significantly increased DLQI score by 5.49 points (95% CI, 1.47–9.51) (P = 0.0089). Compared with AEs involving 0 to 1 system, AEs affecting 2 to 3 systems resulted in a significant increase in the DLQI score by 5.75 points (95% CI, 1.67–9.83) (P = 0.0071). Generalized linear models showed no statistically significant associations between AEs and the HADS scores. Conclusion: Our study demonstrates a high incidence of acitretin-related AEs. These AEs may affect quality of life but rarely cause psychological problems such as anxiety and depression.
{"title":"Impact of Adverse Events Associated With Acitretin Treatment of Moderate-to-Severe Plaque Psoriasis: Based on an Observational, Single-Center Study in Shanghai, China","authors":"Xiaoyuan Zhong, Ying Li, Rui Ma, Xin Wang, Yingyuan Yu, N. Yu, Yangfeng Ding, Jiajing Lu, Yuling Shi","doi":"10.1097/JD9.0000000000000314","DOIUrl":"https://doi.org/10.1097/JD9.0000000000000314","url":null,"abstract":"Objective: Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events (AEs) among individuals. This study aimed to determine the impact of AEs associated with acitretin treatment of moderate-to-severe plaque psoriasis on the Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS) scores. Methods: This prospective, observational, single-center study was conducted from March 2021 to June 2022 and analyzed 116 patients with moderate-to-severe plaque psoriasis treated with acitretin who were followed up for 12 weeks. The primary outcome was the incidence of AEs related to acitretin, and the secondary objective was to investigate the effect of AEs on the DLQI and HADS scores. The generalized linear models were used to assess the association between AEs related to acitretin and DLQI scores or HADS scores, and the association between the involved system/tissue and DLQI scores or HADS scores. Results: A final total of 45 patients were included in the analysis, and a total of 157 treatment-related AEs involving nine organs or systems were reported in 41 patients. The most common AE was skin- or mucosa-related, with 72 cumulative events in 31 patients. AEs also commonly affected the endocrine, digestive, and genitourinary systems. Compared with the group with 0–2 AEs, the group with 3–5 AEs had a significantly increased DLQI score by 5.49 points (95% CI, 1.47–9.51) (P = 0.0089). Compared with AEs involving 0 to 1 system, AEs affecting 2 to 3 systems resulted in a significant increase in the DLQI score by 5.75 points (95% CI, 1.67–9.83) (P = 0.0071). Generalized linear models showed no statistically significant associations between AEs and the HADS scores. Conclusion: Our study demonstrates a high incidence of acitretin-related AEs. These AEs may affect quality of life but rarely cause psychological problems such as anxiety and depression.","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":"6 1","pages":"61 - 66"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44192736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1097/JD9.0000000000000270
Q. Tan, H. Yang, Lili Lan, Ling Xie, Ru-Bing Lin, Chunlei Wan, Longnian Li
Introduction: Erythropoietic protoporphyria (EPP) is a rare photodermatosis mainly caused by deficiency of the enzyme ferrochelatase (FECH). We herein report a case of EPP associated with 2 novel mutations in FECH. Case presentation: A 15-year-old boy experienced pain and pruritus after sunlight exposure. He had occasional claret-red urine, hepatomegaly with increased alanine aminotransferase and aspartate aminotransferase levels, and an elevated free erythrocyte protoporphyrin level. He was treated with oral β-carotene and cholestyramine and avoidance of sunlight as much as possible. Discussion: Genome sequencing revealed 2 novel FECH mutations that had been inherited from his healthy parents. Pathogenicity analysis involving prediction using PolyPhen-2, SIFT, and Mutation Taster revealed that the 2 novel mutations were likely pathogenic. Although the patient’s parents were healthy, they each had one of these 2 mutations. This finding is consistent with previous reports stating that individuals carrying low-expression alleles can be asymptomatic. The pathogenesis of the disease caused by these 2 mutations requires verification by larger and more detailed studies. Conclusion: Although the precise role of these mutations in EPP is not clear, the findings in the present case expand the genotypic spectrum of the disease.
{"title":"Two Novel Mutations in FECH in a Patient With Erythropoietic Protoporphyria: A Case Report","authors":"Q. Tan, H. Yang, Lili Lan, Ling Xie, Ru-Bing Lin, Chunlei Wan, Longnian Li","doi":"10.1097/JD9.0000000000000270","DOIUrl":"https://doi.org/10.1097/JD9.0000000000000270","url":null,"abstract":"Introduction: Erythropoietic protoporphyria (EPP) is a rare photodermatosis mainly caused by deficiency of the enzyme ferrochelatase (FECH). We herein report a case of EPP associated with 2 novel mutations in FECH. Case presentation: A 15-year-old boy experienced pain and pruritus after sunlight exposure. He had occasional claret-red urine, hepatomegaly with increased alanine aminotransferase and aspartate aminotransferase levels, and an elevated free erythrocyte protoporphyrin level. He was treated with oral β-carotene and cholestyramine and avoidance of sunlight as much as possible. Discussion: Genome sequencing revealed 2 novel FECH mutations that had been inherited from his healthy parents. Pathogenicity analysis involving prediction using PolyPhen-2, SIFT, and Mutation Taster revealed that the 2 novel mutations were likely pathogenic. Although the patient’s parents were healthy, they each had one of these 2 mutations. This finding is consistent with previous reports stating that individuals carrying low-expression alleles can be asymptomatic. The pathogenesis of the disease caused by these 2 mutations requires verification by larger and more detailed studies. Conclusion: Although the precise role of these mutations in EPP is not clear, the findings in the present case expand the genotypic spectrum of the disease.","PeriodicalId":34265,"journal":{"name":"International Journal of Dermatology and Venerology","volume":"6 1","pages":"112 - 114"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61780344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：